"The pathologic mechanisms leading to moderate enlargement and marked enlargement might be different, thus making different responses to steroids and IVIG. More work should be done to explore the ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) results in disability through immune-mediated nerve injury, which can lead to irreversible deficits after the inflammatory component of CIDP is ...

Please provide your email address to receive an email when new articles are posted on . Gammagard Liquid is an immune globulin infusion (human) 10% solution. It is the only IV-based immunoglobulin ...

As many as four percent of the world’s population lives with an autoimmune disease, in which the immune system fails to distinguish between ‘self’ and ‘non-self’ and mistakenly attacks the body, ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant ...

PHOENIX — Subcutaneous efgartigimod PH20 SC shows efficacy and tolerability in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), providing a convenient alternative to ...

argenx has released preliminary results from the ADHERE trial, which tested VYVGART Hytrulo on adults with chronic inflammatory demyelinating polyneuropathy (CIDP), where the trial results were ...

VYVGART HYTRULO faces a new FDA safety signal related to CIDP, but I believe this is not a major concern for the franchise. The main issue is the transition from IVIg to VYVGART HYTRULO in real-world ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced full results from the pivotal Phase 3 ADVANCE-CIDP 1 clinical trial investigating HYQVIA® [Immune Globulin ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) may be a rare disease, but it is one of the most common forms of neuropathy and the most common form of chronic autoimmune neuropathy. Roughly ...

In 2014, Baxter got HyQvia over the FDA finish line for patients with primary immunodeficiency (PI). Eight years and three companies later, Takeda is finding more uses for the subcutaneous treatment.